Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 63629-8748

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63629-8748). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

The image shows a single Duloxetine 60 mg delayed-release pellet capsule with an opaque body and a dark-colored cap. This oral capsule is labeled as a human prescription drug by Bryant Ranch Prepack. The product is visually represented without packaging or additional text visible.*

FDA Label Image

Figure6 (Image 10)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. The graph compares pain relief outcomes across increasing thresholds of pain improvement, with Duloxetine groups generally showing higher patient improvement percentages than placebo.*

FDA Label Image

Figure8 (Image 11)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine Delayed-Release 60/120 mg once daily and placebo. The vertical axis shows percentage of patients improved (0-100%), and the horizontal axis shows percent improvement in pain from baseline (0-100%). Duloxetine shows higher patient improvement than placebo across most pain improvement levels.*

FDA Label Image

Figure9 (Image 12)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline with two treatments: placebo and Duloxetine Delayed-Release 60 mg once daily capsules. The graph shows two lines, one for placebo marked with crosses and one for Duloxetine marked with diamonds, illustrating patient improvement distribution across various pain improvement percentages.*

FDA Label Image

Figure10 (Image 13)

A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). The chart contrasts placebo treatment with Duloxetine delayed-release 60/120 mg once daily, showing higher patient improvement percentages for Duloxetine across pain improvement intervals from greater than 0% to 100%.*

FDA Label Image

1 (Image 2)

Duloxetine 60 mg delayed release pellets capsules blister pack from Bryant Ranch Prepack. The foil strip contains multiple capsules, each visibly encapsulated, with printed labeling elements including dosage and product identification codes.*

FDA Label Image

1 (Image 3)

Duloxetine 60 mg delayed release pellets in a capsule, presented in a clear gel-like form with visible pellets inside. The capsule is orange and white, shown on a white background with the labeler Bryant Ranch Prepack. The image focuses on the capsule's physical appearance for oral use.*

FDA Label Image

1 (Image 4)

Chemical structure of Duloxetine shown as a molecular diagram depicting the arrangement of its atoms and bonds, including aromatic rings and functional groups relevant to the active ingredient.*

FDA Label Image

Figure1 (Image 5)

Kaplan-Meier survival curve graph showing the proportion of patients with relapse over time (days) from randomization, comparing Duloxetine delayed-release capsules to placebo. The y-axis represents the proportion of patients with relapse, and the x-axis shows time from randomization to relapse in days.*

FDA Label Image

Figure2 (Image 6)

A Kaplan-Meier survival curve graph showing the proportion of patients with relapse over time for two treatments: placebo and duloxetine delayed-release capsules. The x-axis represents time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. The graph compares relapse rates between the placebo group and the duloxetine delayed-release capsules group.*

FDA Label Image

Figure3 (Image 7)

A line graph displaying the percentage of patients improved over a range of percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. The y-axis represents the percentage of patients improved, ranging from 0 to 90%. The x-axis shows percent improvement in pain from 0% to 100%. Lines slope downward as percent improvement increases.*

FDA Label Image

Figure4 (Image 8)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The vertical axis represents the percentage of patients improved, and the horizontal axis represents percent improvement in pain from baseline.*

FDA Label Image

Figure5 (Image 9)

A line graph comparing the percentage of patients improved based on percent improvement in pain from baseline for Duloxetine 60 mg taken twice daily, Duloxetine 60 mg once daily, and placebo. The x-axis shows percent improvement in pain from 0 to 100. The y-axis shows the percentage of patients improved from 0 to 100. The graph shows higher patient improvement percentages for both Duloxetine dosing regimens compared to placebo across various pain improvement percentages.*

FDA Label Image

Label (Lbl636298748)

Duloxetine Delayed-Release Capsules, USP 60 mg label from Bryant Ranch Prepack. The label features the NDC 63629-8748-1, states the product is prescription only, and shows a package count of 30 capsules. Storage and handling instructions are included along with manufacturer and relabeler information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.